nodes	percent_of_prediction	percent_of_DWPC	metapath
Gadoxetate—ABCC3—Fluorouracil—urinary bladder cancer	0.104	0.133	CbGbCtD
Gadoxetate—ABCC3—Cisplatin—urinary bladder cancer	0.0884	0.113	CbGbCtD
Gadoxetate—ABCC3—Etoposide—urinary bladder cancer	0.0869	0.111	CbGbCtD
Gadoxetate—ABCC4—Fluorouracil—urinary bladder cancer	0.0795	0.102	CbGbCtD
Gadoxetate—ABCC3—Doxorubicin—urinary bladder cancer	0.0593	0.076	CbGbCtD
Gadoxetate—ABCC3—Methotrexate—urinary bladder cancer	0.0574	0.0736	CbGbCtD
Gadoxetate—SLCO1B3—Methotrexate—urinary bladder cancer	0.051	0.0654	CbGbCtD
Gadoxetate—ABCC2—Carboplatin—urinary bladder cancer	0.047	0.0603	CbGbCtD
Gadoxetate—ABCC4—Methotrexate—urinary bladder cancer	0.0439	0.0562	CbGbCtD
Gadoxetate—ABCC2—Cisplatin—urinary bladder cancer	0.0402	0.0515	CbGbCtD
Gadoxetate—ABCC2—Etoposide—urinary bladder cancer	0.0395	0.0506	CbGbCtD
Gadoxetate—SLCO1B1—Methotrexate—urinary bladder cancer	0.0297	0.0381	CbGbCtD
Gadoxetate—ABCC2—Doxorubicin—urinary bladder cancer	0.0269	0.0345	CbGbCtD
Gadoxetate—ABCC2—Methotrexate—urinary bladder cancer	0.0261	0.0334	CbGbCtD
Gadoxetate—ABCC3—Codeine and Morphine Metabolism—UGT2B7—urinary bladder cancer	0.00575	0.146	CbGpPWpGaD
Gadoxetate—ABCC2—Codeine and Morphine Metabolism—UGT2B7—urinary bladder cancer	0.00456	0.115	CbGpPWpGaD
Gadoxetate—SLCO1B1—Codeine and Morphine Metabolism—UGT2B7—urinary bladder cancer	0.00428	0.108	CbGpPWpGaD
Gadoxetate—ABCC3—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP4B1—urinary bladder cancer	0.00163	0.0412	CbGpPWpGaD
Gadoxetate—ABCC2—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP4B1—urinary bladder cancer	0.00129	0.0326	CbGpPWpGaD
Gadoxetate—ABCC3—Fluoropyrimidine Activity—TYMP—urinary bladder cancer	0.00123	0.031	CbGpPWpGaD
Gadoxetate—ABCC4—Fluoropyrimidine Activity—TYMP—urinary bladder cancer	0.00115	0.0292	CbGpPWpGaD
Gadoxetate—ABCC3—Fluoropyrimidine Activity—RRM2—urinary bladder cancer	0.000956	0.0242	CbGpPWpGaD
Gadoxetate—ABCC4—Fluoropyrimidine Activity—RRM2—urinary bladder cancer	0.000899	0.0228	CbGpPWpGaD
Gadoxetate—ABCC3—prostate gland—urinary bladder cancer	0.000879	0.113	CbGeAlD
Gadoxetate—ABCC3—Constitutive Androstane Receptor Pathway—SMC1A—urinary bladder cancer	0.000833	0.0211	CbGpPWpGaD
Gadoxetate—SLCO1B3—vagina—urinary bladder cancer	0.000791	0.101	CbGeAlD
Gadoxetate—ABCC4—prostate gland—urinary bladder cancer	0.000725	0.093	CbGeAlD
Gadoxetate—ABCC2—prostate gland—urinary bladder cancer	0.000702	0.09	CbGeAlD
Gadoxetate—ABCC2—Constitutive Androstane Receptor Pathway—SMC1A—urinary bladder cancer	0.000661	0.0167	CbGpPWpGaD
Gadoxetate—SLCO1B1—renal system—urinary bladder cancer	0.000631	0.0809	CbGeAlD
Gadoxetate—ABCC3—renal system—urinary bladder cancer	0.000599	0.0768	CbGeAlD
Gadoxetate—ABCC3—NRF2 pathway—UGT2B7—urinary bladder cancer	0.000563	0.0143	CbGpPWpGaD
Gadoxetate—ABCC3—Fluoropyrimidine Activity—TYMS—urinary bladder cancer	0.000554	0.014	CbGpPWpGaD
Gadoxetate—ABCC4—NRF2 pathway—UGT2B7—urinary bladder cancer	0.000529	0.0134	CbGpPWpGaD
Gadoxetate—ABCC4—Fluoropyrimidine Activity—TYMS—urinary bladder cancer	0.00052	0.0132	CbGpPWpGaD
Gadoxetate—ABCC3—Fluoropyrimidine Activity—ERCC2—urinary bladder cancer	0.000514	0.013	CbGpPWpGaD
Gadoxetate—SLCO1B1—female reproductive system—urinary bladder cancer	0.000506	0.0648	CbGeAlD
Gadoxetate—ABCC4—renal system—urinary bladder cancer	0.000494	0.0634	CbGeAlD
Gadoxetate—ABCC4—Fluoropyrimidine Activity—ERCC2—urinary bladder cancer	0.000484	0.0122	CbGpPWpGaD
Gadoxetate—ABCC3—Fluoropyrimidine Activity—MTHFR—urinary bladder cancer	0.000484	0.0122	CbGpPWpGaD
Gadoxetate—ABCC3—female reproductive system—urinary bladder cancer	0.00048	0.0615	CbGeAlD
Gadoxetate—ABCC2—renal system—urinary bladder cancer	0.000479	0.0613	CbGeAlD
Gadoxetate—ABCC4—Fluoropyrimidine Activity—MTHFR—urinary bladder cancer	0.000455	0.0115	CbGpPWpGaD
Gadoxetate—ABCC2—NRF2 pathway—UGT2B7—urinary bladder cancer	0.000446	0.0113	CbGpPWpGaD
Gadoxetate—SLCO1B3—SLC-mediated transmembrane transport—SLC14A2—urinary bladder cancer	0.00043	0.0109	CbGpPWpGaD
Gadoxetate—ABCC4—female reproductive system—urinary bladder cancer	0.000396	0.0507	CbGeAlD
Gadoxetate—ABCC2—female reproductive system—urinary bladder cancer	0.000383	0.0491	CbGeAlD
Gadoxetate—ABCC3—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	0.000383	0.0097	CbGpPWpGaD
Gadoxetate—ABCC2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	0.000304	0.00769	CbGpPWpGaD
Gadoxetate—SLCO1B1—SLC-mediated transmembrane transport—SLC14A2—urinary bladder cancer	0.000289	0.00731	CbGpPWpGaD
Gadoxetate—ABCC3—lymph node—urinary bladder cancer	0.000281	0.036	CbGeAlD
Gadoxetate—ABCC4—lymph node—urinary bladder cancer	0.000232	0.0297	CbGeAlD
Gadoxetate—ABCC2—lymph node—urinary bladder cancer	0.000224	0.0287	CbGeAlD
Gadoxetate—SLCO1B3—Transmembrane transport of small molecules—SLC14A2—urinary bladder cancer	0.000218	0.00553	CbGpPWpGaD
Gadoxetate—ABCC3—NRF2 pathway—NQO1—urinary bladder cancer	0.000217	0.0055	CbGpPWpGaD
Gadoxetate—ABCC4—NRF2 pathway—NQO1—urinary bladder cancer	0.000204	0.00517	CbGpPWpGaD
Gadoxetate—ABCC3—Transmembrane transport of small molecules—SLC14A2—urinary bladder cancer	0.000197	0.00499	CbGpPWpGaD
Gadoxetate—SLCO1B3—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	0.000189	0.00479	CbGpPWpGaD
Gadoxetate—ABCC4—Transmembrane transport of small molecules—SLC14A2—urinary bladder cancer	0.000185	0.00469	CbGpPWpGaD
Gadoxetate—ABCC3—Fluoropyrimidine Activity—TP53—urinary bladder cancer	0.000184	0.00465	CbGpPWpGaD
Gadoxetate—ABCC3—NRF2 pathway—GSTP1—urinary bladder cancer	0.000181	0.00459	CbGpPWpGaD
Gadoxetate—Decreased appetite—Fluorouracil—urinary bladder cancer	0.000176	0.00102	CcSEcCtD
Gadoxetate—Anaphylactic shock—Etoposide—urinary bladder cancer	0.000176	0.00102	CcSEcCtD
Gadoxetate—Asthenia—Thiotepa—urinary bladder cancer	0.000175	0.00101	CcSEcCtD
Gadoxetate—Gastrointestinal disorder—Fluorouracil—urinary bladder cancer	0.000174	0.00101	CcSEcCtD
Gadoxetate—Infection—Etoposide—urinary bladder cancer	0.000174	0.00101	CcSEcCtD
Gadoxetate—Abdominal distension—Epirubicin—urinary bladder cancer	0.000174	0.00101	CcSEcCtD
Gadoxetate—Blood creatinine increased—Doxorubicin—urinary bladder cancer	0.000174	0.001	CcSEcCtD
Gadoxetate—Dysphagia—Epirubicin—urinary bladder cancer	0.000173	0.001	CcSEcCtD
Gadoxetate—Pruritus—Thiotepa—urinary bladder cancer	0.000173	0.001	CcSEcCtD
Gadoxetate—ABCC4—Fluoropyrimidine Activity—TP53—urinary bladder cancer	0.000173	0.00437	CbGpPWpGaD
Gadoxetate—Dehydration—Doxorubicin—urinary bladder cancer	0.000172	0.000997	CcSEcCtD
Gadoxetate—ABCC2—NRF2 pathway—NQO1—urinary bladder cancer	0.000172	0.00436	CbGpPWpGaD
Gadoxetate—ABCC4—Platelet degranulation—IGF1—urinary bladder cancer	0.000172	0.00436	CbGpPWpGaD
Gadoxetate—Paraesthesia—Cisplatin—urinary bladder cancer	0.000172	0.000996	CcSEcCtD
Gadoxetate—Tachycardia—Etoposide—urinary bladder cancer	0.000171	0.000991	CcSEcCtD
Gadoxetate—Dyspnoea—Cisplatin—urinary bladder cancer	0.000171	0.000989	CcSEcCtD
Gadoxetate—ABCC3—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	0.000171	0.00432	CbGpPWpGaD
Gadoxetate—Skin disorder—Etoposide—urinary bladder cancer	0.000171	0.000987	CcSEcCtD
Gadoxetate—ABCC4—NRF2 pathway—GSTP1—urinary bladder cancer	0.00017	0.00431	CbGpPWpGaD
Gadoxetate—Hyperhidrosis—Etoposide—urinary bladder cancer	0.00017	0.000982	CcSEcCtD
Gadoxetate—Feeling abnormal—Gemcitabine—urinary bladder cancer	0.000169	0.00098	CcSEcCtD
Gadoxetate—Hypokalaemia—Doxorubicin—urinary bladder cancer	0.000169	0.000976	CcSEcCtD
Gadoxetate—Anorexia—Etoposide—urinary bladder cancer	0.000167	0.000968	CcSEcCtD
Gadoxetate—Diarrhoea—Thiotepa—urinary bladder cancer	0.000167	0.000968	CcSEcCtD
Gadoxetate—Decreased appetite—Cisplatin—urinary bladder cancer	0.000167	0.000964	CcSEcCtD
Gadoxetate—Feeling abnormal—Fluorouracil—urinary bladder cancer	0.000167	0.000964	CcSEcCtD
Gadoxetate—ABCC3—NRF2 pathway—GSTM1—urinary bladder cancer	0.000167	0.00422	CbGpPWpGaD
Gadoxetate—Bronchitis—Epirubicin—urinary bladder cancer	0.000166	0.000963	CcSEcCtD
Gadoxetate—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.000165	0.000957	CcSEcCtD
Gadoxetate—ABCC4—Response to elevated platelet cytosolic Ca2+—IGF1—urinary bladder cancer	0.000164	0.00416	CbGpPWpGaD
Gadoxetate—Hypotension—Etoposide—urinary bladder cancer	0.000164	0.000949	CcSEcCtD
Gadoxetate—Body temperature increased—Gemcitabine—urinary bladder cancer	0.000163	0.00094	CcSEcCtD
Gadoxetate—Renal failure—Methotrexate—urinary bladder cancer	0.000162	0.000938	CcSEcCtD
Gadoxetate—Dizziness—Thiotepa—urinary bladder cancer	0.000162	0.000935	CcSEcCtD
Gadoxetate—Abdominal distension—Doxorubicin—urinary bladder cancer	0.000161	0.000933	CcSEcCtD
Gadoxetate—Urticaria—Fluorouracil—urinary bladder cancer	0.000161	0.000929	CcSEcCtD
Gadoxetate—Conjunctivitis—Methotrexate—urinary bladder cancer	0.00016	0.000927	CcSEcCtD
Gadoxetate—Dysphagia—Doxorubicin—urinary bladder cancer	0.00016	0.000927	CcSEcCtD
Gadoxetate—Body temperature increased—Fluorouracil—urinary bladder cancer	0.00016	0.000925	CcSEcCtD
Gadoxetate—SLCO1B3—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	0.000158	0.004	CbGpPWpGaD
Gadoxetate—Feeling abnormal—Cisplatin—urinary bladder cancer	0.000158	0.000914	CcSEcCtD
Gadoxetate—Paraesthesia—Etoposide—urinary bladder cancer	0.000158	0.000912	CcSEcCtD
Gadoxetate—ABCC4—NRF2 pathway—GSTM1—urinary bladder cancer	0.000157	0.00396	CbGpPWpGaD
Gadoxetate—Dyspnoea—Etoposide—urinary bladder cancer	0.000156	0.000906	CcSEcCtD
Gadoxetate—ABCC2—Transmembrane transport of small molecules—SLC14A2—urinary bladder cancer	0.000156	0.00396	CbGpPWpGaD
Gadoxetate—Vomiting—Thiotepa—urinary bladder cancer	0.000155	0.000899	CcSEcCtD
Gadoxetate—Rash—Thiotepa—urinary bladder cancer	0.000154	0.000892	CcSEcCtD
Gadoxetate—Bronchitis—Doxorubicin—urinary bladder cancer	0.000154	0.000891	CcSEcCtD
Gadoxetate—Dermatitis—Thiotepa—urinary bladder cancer	0.000154	0.000891	CcSEcCtD
Gadoxetate—Headache—Thiotepa—urinary bladder cancer	0.000153	0.000886	CcSEcCtD
Gadoxetate—Decreased appetite—Etoposide—urinary bladder cancer	0.000153	0.000883	CcSEcCtD
Gadoxetate—Renal failure—Epirubicin—urinary bladder cancer	0.000152	0.000878	CcSEcCtD
Gadoxetate—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.000152	0.000877	CcSEcCtD
Gadoxetate—Body temperature increased—Cisplatin—urinary bladder cancer	0.000151	0.000877	CcSEcCtD
Gadoxetate—Fatigue—Etoposide—urinary bladder cancer	0.000151	0.000876	CcSEcCtD
Gadoxetate—Constipation—Etoposide—urinary bladder cancer	0.00015	0.000869	CcSEcCtD
Gadoxetate—Conjunctivitis—Epirubicin—urinary bladder cancer	0.00015	0.000868	CcSEcCtD
Gadoxetate—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.000149	0.000862	CcSEcCtD
Gadoxetate—Asthenia—Gemcitabine—urinary bladder cancer	0.000147	0.000854	CcSEcCtD
Gadoxetate—SLCO1B1—Transmembrane transport of small molecules—SLC14A2—urinary bladder cancer	0.000147	0.00372	CbGpPWpGaD
Gadoxetate—Pruritus—Gemcitabine—urinary bladder cancer	0.000145	0.000842	CcSEcCtD
Gadoxetate—Nausea—Thiotepa—urinary bladder cancer	0.000145	0.00084	CcSEcCtD
Gadoxetate—Feeling abnormal—Etoposide—urinary bladder cancer	0.000145	0.000837	CcSEcCtD
Gadoxetate—ABCC2—NRF2 pathway—GSTP1—urinary bladder cancer	0.000144	0.00364	CbGpPWpGaD
Gadoxetate—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000144	0.000831	CcSEcCtD
Gadoxetate—Pruritus—Fluorouracil—urinary bladder cancer	0.000143	0.000828	CcSEcCtD
Gadoxetate—ABCC3—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	0.000142	0.00361	CbGpPWpGaD
Gadoxetate—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000141	0.000817	CcSEcCtD
Gadoxetate—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000141	0.000814	CcSEcCtD
Gadoxetate—Renal failure—Doxorubicin—urinary bladder cancer	0.00014	0.000812	CcSEcCtD
Gadoxetate—Urticaria—Etoposide—urinary bladder cancer	0.000139	0.000807	CcSEcCtD
Gadoxetate—Rhinitis—Epirubicin—urinary bladder cancer	0.000139	0.000804	CcSEcCtD
Gadoxetate—Abdominal pain—Etoposide—urinary bladder cancer	0.000139	0.000803	CcSEcCtD
Gadoxetate—Body temperature increased—Etoposide—urinary bladder cancer	0.000139	0.000803	CcSEcCtD
Gadoxetate—Conjunctivitis—Doxorubicin—urinary bladder cancer	0.000139	0.000803	CcSEcCtD
Gadoxetate—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000138	0.0008	CcSEcCtD
Gadoxetate—Hypoaesthesia—Epirubicin—urinary bladder cancer	0.000138	0.000798	CcSEcCtD
Gadoxetate—Asthenia—Cisplatin—urinary bladder cancer	0.000137	0.000796	CcSEcCtD
Gadoxetate—Cardiac disorder—Methotrexate—urinary bladder cancer	0.000137	0.000795	CcSEcCtD
Gadoxetate—Connective tissue disorder—Epirubicin—urinary bladder cancer	0.000136	0.000788	CcSEcCtD
Gadoxetate—Angiopathy—Methotrexate—urinary bladder cancer	0.000134	0.000777	CcSEcCtD
Gadoxetate—ABCC4—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	0.000134	0.00339	CbGpPWpGaD
Gadoxetate—Immune system disorder—Methotrexate—urinary bladder cancer	0.000134	0.000774	CcSEcCtD
Gadoxetate—Dizziness—Fluorouracil—urinary bladder cancer	0.000134	0.000774	CcSEcCtD
Gadoxetate—Mediastinal disorder—Methotrexate—urinary bladder cancer	0.000133	0.000772	CcSEcCtD
Gadoxetate—Chills—Methotrexate—urinary bladder cancer	0.000133	0.000769	CcSEcCtD
Gadoxetate—ABCC2—NRF2 pathway—GSTM1—urinary bladder cancer	0.000132	0.00334	CbGpPWpGaD
Gadoxetate—Diarrhoea—Cisplatin—urinary bladder cancer	0.000131	0.000759	CcSEcCtD
Gadoxetate—Vomiting—Gemcitabine—urinary bladder cancer	0.000131	0.000756	CcSEcCtD
Gadoxetate—Rash—Gemcitabine—urinary bladder cancer	0.00013	0.00075	CcSEcCtD
Gadoxetate—Dermatitis—Gemcitabine—urinary bladder cancer	0.000129	0.000749	CcSEcCtD
Gadoxetate—Hypersensitivity—Etoposide—urinary bladder cancer	0.000129	0.000748	CcSEcCtD
Gadoxetate—Headache—Gemcitabine—urinary bladder cancer	0.000129	0.000745	CcSEcCtD
Gadoxetate—SLCO1B3—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	0.000129	0.00326	CbGpPWpGaD
Gadoxetate—Cardiac disorder—Epirubicin—urinary bladder cancer	0.000129	0.000744	CcSEcCtD
Gadoxetate—Flushing—Epirubicin—urinary bladder cancer	0.000129	0.000744	CcSEcCtD
Gadoxetate—Vomiting—Fluorouracil—urinary bladder cancer	0.000129	0.000744	CcSEcCtD
Gadoxetate—Rhinitis—Doxorubicin—urinary bladder cancer	0.000128	0.000744	CcSEcCtD
Gadoxetate—Hypoaesthesia—Doxorubicin—urinary bladder cancer	0.000128	0.000738	CcSEcCtD
Gadoxetate—Rash—Fluorouracil—urinary bladder cancer	0.000127	0.000738	CcSEcCtD
Gadoxetate—Dermatitis—Fluorouracil—urinary bladder cancer	0.000127	0.000737	CcSEcCtD
Gadoxetate—SLCO1B1—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	0.000127	0.00322	CbGpPWpGaD
Gadoxetate—Headache—Fluorouracil—urinary bladder cancer	0.000127	0.000733	CcSEcCtD
Gadoxetate—Dysgeusia—Methotrexate—urinary bladder cancer	0.000126	0.00073	CcSEcCtD
Gadoxetate—Asthenia—Etoposide—urinary bladder cancer	0.000126	0.000729	CcSEcCtD
Gadoxetate—Connective tissue disorder—Doxorubicin—urinary bladder cancer	0.000126	0.000729	CcSEcCtD
Gadoxetate—Angiopathy—Epirubicin—urinary bladder cancer	0.000126	0.000727	CcSEcCtD
Gadoxetate—Immune system disorder—Epirubicin—urinary bladder cancer	0.000125	0.000724	CcSEcCtD
Gadoxetate—Mediastinal disorder—Epirubicin—urinary bladder cancer	0.000125	0.000722	CcSEcCtD
Gadoxetate—Back pain—Methotrexate—urinary bladder cancer	0.000125	0.000721	CcSEcCtD
Gadoxetate—Chills—Epirubicin—urinary bladder cancer	0.000124	0.000719	CcSEcCtD
Gadoxetate—Pruritus—Etoposide—urinary bladder cancer	0.000124	0.000719	CcSEcCtD
Gadoxetate—Arrhythmia—Epirubicin—urinary bladder cancer	0.000124	0.000716	CcSEcCtD
Gadoxetate—Nausea—Gemcitabine—urinary bladder cancer	0.000122	0.000707	CcSEcCtD
Gadoxetate—Vomiting—Cisplatin—urinary bladder cancer	0.000122	0.000705	CcSEcCtD
Gadoxetate—Vision blurred—Methotrexate—urinary bladder cancer	0.000121	0.000703	CcSEcCtD
Gadoxetate—Rash—Cisplatin—urinary bladder cancer	0.000121	0.000699	CcSEcCtD
Gadoxetate—Dermatitis—Cisplatin—urinary bladder cancer	0.000121	0.000699	CcSEcCtD
Gadoxetate—Diarrhoea—Etoposide—urinary bladder cancer	0.00012	0.000695	CcSEcCtD
Gadoxetate—Nausea—Fluorouracil—urinary bladder cancer	0.00012	0.000695	CcSEcCtD
Gadoxetate—Ill-defined disorder—Methotrexate—urinary bladder cancer	0.00012	0.000692	CcSEcCtD
Gadoxetate—Flushing—Doxorubicin—urinary bladder cancer	0.000119	0.000688	CcSEcCtD
Gadoxetate—Cardiac disorder—Doxorubicin—urinary bladder cancer	0.000119	0.000688	CcSEcCtD
Gadoxetate—Flatulence—Epirubicin—urinary bladder cancer	0.000119	0.000688	CcSEcCtD
Gadoxetate—Dysgeusia—Epirubicin—urinary bladder cancer	0.000118	0.000683	CcSEcCtD
Gadoxetate—Back pain—Epirubicin—urinary bladder cancer	0.000117	0.000675	CcSEcCtD
Gadoxetate—Angiopathy—Doxorubicin—urinary bladder cancer	0.000116	0.000673	CcSEcCtD
Gadoxetate—Malaise—Methotrexate—urinary bladder cancer	0.000116	0.000672	CcSEcCtD
Gadoxetate—ABCC3—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	0.000116	0.00294	CbGpPWpGaD
Gadoxetate—Dizziness—Etoposide—urinary bladder cancer	0.000116	0.000672	CcSEcCtD
Gadoxetate—Immune system disorder—Doxorubicin—urinary bladder cancer	0.000116	0.00067	CcSEcCtD
Gadoxetate—Vertigo—Methotrexate—urinary bladder cancer	0.000116	0.00067	CcSEcCtD
Gadoxetate—Mediastinal disorder—Doxorubicin—urinary bladder cancer	0.000115	0.000668	CcSEcCtD
Gadoxetate—Chills—Doxorubicin—urinary bladder cancer	0.000115	0.000665	CcSEcCtD
Gadoxetate—Arrhythmia—Doxorubicin—urinary bladder cancer	0.000114	0.000663	CcSEcCtD
Gadoxetate—Nausea—Cisplatin—urinary bladder cancer	0.000114	0.000659	CcSEcCtD
Gadoxetate—Vision blurred—Epirubicin—urinary bladder cancer	0.000114	0.000658	CcSEcCtD
Gadoxetate—ABCC2—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	0.000113	0.00286	CbGpPWpGaD
Gadoxetate—Cough—Methotrexate—urinary bladder cancer	0.000112	0.000651	CcSEcCtD
Gadoxetate—Ill-defined disorder—Epirubicin—urinary bladder cancer	0.000112	0.000647	CcSEcCtD
Gadoxetate—Convulsion—Methotrexate—urinary bladder cancer	0.000112	0.000646	CcSEcCtD
Gadoxetate—Vomiting—Etoposide—urinary bladder cancer	0.000112	0.000646	CcSEcCtD
Gadoxetate—Agitation—Epirubicin—urinary bladder cancer	0.000111	0.000641	CcSEcCtD
Gadoxetate—Rash—Etoposide—urinary bladder cancer	0.000111	0.000641	CcSEcCtD
Gadoxetate—Dermatitis—Etoposide—urinary bladder cancer	0.000111	0.00064	CcSEcCtD
Gadoxetate—Headache—Etoposide—urinary bladder cancer	0.00011	0.000636	CcSEcCtD
Gadoxetate—Flatulence—Doxorubicin—urinary bladder cancer	0.00011	0.000636	CcSEcCtD
Gadoxetate—Chest pain—Methotrexate—urinary bladder cancer	0.00011	0.000635	CcSEcCtD
Gadoxetate—Dysgeusia—Doxorubicin—urinary bladder cancer	0.000109	0.000632	CcSEcCtD
Gadoxetate—ABCC4—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	0.000109	0.00277	CbGpPWpGaD
Gadoxetate—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.000109	0.00063	CcSEcCtD
Gadoxetate—Malaise—Epirubicin—urinary bladder cancer	0.000109	0.000629	CcSEcCtD
Gadoxetate—Discomfort—Methotrexate—urinary bladder cancer	0.000108	0.000627	CcSEcCtD
Gadoxetate—Vertigo—Epirubicin—urinary bladder cancer	0.000108	0.000627	CcSEcCtD
Gadoxetate—Syncope—Epirubicin—urinary bladder cancer	0.000108	0.000626	CcSEcCtD
Gadoxetate—SLCO1B3—Metabolism—GSTZ1—urinary bladder cancer	0.000108	0.00273	CbGpPWpGaD
Gadoxetate—Back pain—Doxorubicin—urinary bladder cancer	0.000108	0.000625	CcSEcCtD
Gadoxetate—Palpitations—Epirubicin—urinary bladder cancer	0.000107	0.000617	CcSEcCtD
Gadoxetate—SLCO1B1—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	0.000106	0.00269	CbGpPWpGaD
Gadoxetate—Loss of consciousness—Epirubicin—urinary bladder cancer	0.000106	0.000613	CcSEcCtD
Gadoxetate—Cough—Epirubicin—urinary bladder cancer	0.000105	0.000609	CcSEcCtD
Gadoxetate—Anaphylactic shock—Methotrexate—urinary bladder cancer	0.000105	0.000609	CcSEcCtD
Gadoxetate—Vision blurred—Doxorubicin—urinary bladder cancer	0.000105	0.000608	CcSEcCtD
Gadoxetate—Convulsion—Epirubicin—urinary bladder cancer	0.000104	0.000605	CcSEcCtD
Gadoxetate—Infection—Methotrexate—urinary bladder cancer	0.000104	0.000605	CcSEcCtD
Gadoxetate—Nausea—Etoposide—urinary bladder cancer	0.000104	0.000603	CcSEcCtD
Gadoxetate—Ill-defined disorder—Doxorubicin—urinary bladder cancer	0.000104	0.000599	CcSEcCtD
Gadoxetate—Nervous system disorder—Methotrexate—urinary bladder cancer	0.000103	0.000597	CcSEcCtD
Gadoxetate—Chest pain—Epirubicin—urinary bladder cancer	0.000103	0.000594	CcSEcCtD
Gadoxetate—Agitation—Doxorubicin—urinary bladder cancer	0.000103	0.000593	CcSEcCtD
Gadoxetate—SLCO1B3—Metabolism—GSTO2—urinary bladder cancer	0.000102	0.00259	CbGpPWpGaD
Gadoxetate—SLCO1B3—Metabolism—NAT1—urinary bladder cancer	0.000102	0.00259	CbGpPWpGaD
Gadoxetate—Anxiety—Epirubicin—urinary bladder cancer	0.000102	0.000592	CcSEcCtD
Gadoxetate—Skin disorder—Methotrexate—urinary bladder cancer	0.000102	0.000591	CcSEcCtD
Gadoxetate—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.000102	0.00059	CcSEcCtD
Gadoxetate—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.000102	0.000588	CcSEcCtD
Gadoxetate—Discomfort—Epirubicin—urinary bladder cancer	0.000101	0.000587	CcSEcCtD
Gadoxetate—SLCO1B3—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	0.000101	0.00255	CbGpPWpGaD
Gadoxetate—Malaise—Doxorubicin—urinary bladder cancer	0.000101	0.000582	CcSEcCtD
Gadoxetate—Dry mouth—Epirubicin—urinary bladder cancer	0.0001	0.000581	CcSEcCtD
Gadoxetate—Vertigo—Doxorubicin—urinary bladder cancer	0.0001	0.00058	CcSEcCtD
Gadoxetate—Anorexia—Methotrexate—urinary bladder cancer	0.0001	0.00058	CcSEcCtD
Gadoxetate—Syncope—Doxorubicin—urinary bladder cancer	0.0001	0.000579	CcSEcCtD
Gadoxetate—Palpitations—Doxorubicin—urinary bladder cancer	9.86e-05	0.000571	CcSEcCtD
Gadoxetate—Anaphylactic shock—Epirubicin—urinary bladder cancer	9.84e-05	0.000569	CcSEcCtD
Gadoxetate—Oedema—Epirubicin—urinary bladder cancer	9.84e-05	0.000569	CcSEcCtD
Gadoxetate—Hypotension—Methotrexate—urinary bladder cancer	9.82e-05	0.000569	CcSEcCtD
Gadoxetate—Loss of consciousness—Doxorubicin—urinary bladder cancer	9.8e-05	0.000567	CcSEcCtD
Gadoxetate—Infection—Epirubicin—urinary bladder cancer	9.78e-05	0.000566	CcSEcCtD
Gadoxetate—ABCC3—Metabolism—GSTZ1—urinary bladder cancer	9.74e-05	0.00247	CbGpPWpGaD
Gadoxetate—Cough—Doxorubicin—urinary bladder cancer	9.73e-05	0.000563	CcSEcCtD
Gadoxetate—Shock—Epirubicin—urinary bladder cancer	9.68e-05	0.00056	CcSEcCtD
Gadoxetate—Convulsion—Doxorubicin—urinary bladder cancer	9.67e-05	0.000559	CcSEcCtD
Gadoxetate—Nervous system disorder—Epirubicin—urinary bladder cancer	9.65e-05	0.000558	CcSEcCtD
Gadoxetate—Tachycardia—Epirubicin—urinary bladder cancer	9.6e-05	0.000556	CcSEcCtD
Gadoxetate—Skin disorder—Epirubicin—urinary bladder cancer	9.56e-05	0.000553	CcSEcCtD
Gadoxetate—Hyperhidrosis—Epirubicin—urinary bladder cancer	9.51e-05	0.000551	CcSEcCtD
Gadoxetate—Chest pain—Doxorubicin—urinary bladder cancer	9.5e-05	0.00055	CcSEcCtD
Gadoxetate—Anxiety—Doxorubicin—urinary bladder cancer	9.46e-05	0.000548	CcSEcCtD
Gadoxetate—Paraesthesia—Methotrexate—urinary bladder cancer	9.44e-05	0.000546	CcSEcCtD
Gadoxetate—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	9.43e-05	0.000546	CcSEcCtD
Gadoxetate—Discomfort—Doxorubicin—urinary bladder cancer	9.38e-05	0.000543	CcSEcCtD
Gadoxetate—Anorexia—Epirubicin—urinary bladder cancer	9.38e-05	0.000543	CcSEcCtD
Gadoxetate—Dyspnoea—Methotrexate—urinary bladder cancer	9.37e-05	0.000543	CcSEcCtD
Gadoxetate—SLCO1B3—Metabolism—UGT2B7—urinary bladder cancer	9.36e-05	0.00237	CbGpPWpGaD
Gadoxetate—Dry mouth—Doxorubicin—urinary bladder cancer	9.29e-05	0.000538	CcSEcCtD
Gadoxetate—ABCC3—Metabolism—NAT1—urinary bladder cancer	9.23e-05	0.00234	CbGpPWpGaD
Gadoxetate—ABCC3—Metabolism—GSTO2—urinary bladder cancer	9.23e-05	0.00234	CbGpPWpGaD
Gadoxetate—ABCC2—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	9.21e-05	0.00233	CbGpPWpGaD
Gadoxetate—Hypotension—Epirubicin—urinary bladder cancer	9.19e-05	0.000532	CcSEcCtD
Gadoxetate—Decreased appetite—Methotrexate—urinary bladder cancer	9.14e-05	0.000529	CcSEcCtD
Gadoxetate—Anaphylactic shock—Doxorubicin—urinary bladder cancer	9.1e-05	0.000527	CcSEcCtD
Gadoxetate—Oedema—Doxorubicin—urinary bladder cancer	9.1e-05	0.000527	CcSEcCtD
Gadoxetate—ABCC3—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	9.08e-05	0.0023	CbGpPWpGaD
Gadoxetate—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	9.08e-05	0.000525	CcSEcCtD
Gadoxetate—Fatigue—Methotrexate—urinary bladder cancer	9.06e-05	0.000525	CcSEcCtD
Gadoxetate—Infection—Doxorubicin—urinary bladder cancer	9.04e-05	0.000523	CcSEcCtD
Gadoxetate—Shock—Doxorubicin—urinary bladder cancer	8.96e-05	0.000518	CcSEcCtD
Gadoxetate—Nervous system disorder—Doxorubicin—urinary bladder cancer	8.93e-05	0.000517	CcSEcCtD
Gadoxetate—Tachycardia—Doxorubicin—urinary bladder cancer	8.89e-05	0.000514	CcSEcCtD
Gadoxetate—Skin disorder—Doxorubicin—urinary bladder cancer	8.84e-05	0.000512	CcSEcCtD
Gadoxetate—Paraesthesia—Epirubicin—urinary bladder cancer	8.84e-05	0.000511	CcSEcCtD
Gadoxetate—Hyperhidrosis—Doxorubicin—urinary bladder cancer	8.8e-05	0.000509	CcSEcCtD
Gadoxetate—Dyspnoea—Epirubicin—urinary bladder cancer	8.77e-05	0.000508	CcSEcCtD
Gadoxetate—SLCO1B3—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	8.69e-05	0.0022	CbGpPWpGaD
Gadoxetate—Anorexia—Doxorubicin—urinary bladder cancer	8.68e-05	0.000502	CcSEcCtD
Gadoxetate—Feeling abnormal—Methotrexate—urinary bladder cancer	8.66e-05	0.000501	CcSEcCtD
Gadoxetate—SLCO1B1—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	8.65e-05	0.00219	CbGpPWpGaD
Gadoxetate—Gastrointestinal pain—Methotrexate—urinary bladder cancer	8.6e-05	0.000498	CcSEcCtD
Gadoxetate—Decreased appetite—Epirubicin—urinary bladder cancer	8.55e-05	0.000495	CcSEcCtD
Gadoxetate—Hypotension—Doxorubicin—urinary bladder cancer	8.51e-05	0.000492	CcSEcCtD
Gadoxetate—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	8.49e-05	0.000492	CcSEcCtD
Gadoxetate—Fatigue—Epirubicin—urinary bladder cancer	8.48e-05	0.000491	CcSEcCtD
Gadoxetate—ABCC3—Metabolism—UGT2B7—urinary bladder cancer	8.44e-05	0.00214	CbGpPWpGaD
Gadoxetate—SLCO1B3—Metabolism—CYP4B1—urinary bladder cancer	8.42e-05	0.00213	CbGpPWpGaD
Gadoxetate—Constipation—Epirubicin—urinary bladder cancer	8.41e-05	0.000487	CcSEcCtD
Gadoxetate—Urticaria—Methotrexate—urinary bladder cancer	8.35e-05	0.000483	CcSEcCtD
Gadoxetate—Body temperature increased—Methotrexate—urinary bladder cancer	8.31e-05	0.000481	CcSEcCtD
Gadoxetate—Abdominal pain—Methotrexate—urinary bladder cancer	8.31e-05	0.000481	CcSEcCtD
Gadoxetate—Paraesthesia—Doxorubicin—urinary bladder cancer	8.18e-05	0.000473	CcSEcCtD
Gadoxetate—Dyspnoea—Doxorubicin—urinary bladder cancer	8.12e-05	0.00047	CcSEcCtD
Gadoxetate—Feeling abnormal—Epirubicin—urinary bladder cancer	8.11e-05	0.000469	CcSEcCtD
Gadoxetate—Gastrointestinal pain—Epirubicin—urinary bladder cancer	8.05e-05	0.000466	CcSEcCtD
Gadoxetate—SLCO1B3—Metabolism—SLC19A1—urinary bladder cancer	7.96e-05	0.00201	CbGpPWpGaD
Gadoxetate—Decreased appetite—Doxorubicin—urinary bladder cancer	7.91e-05	0.000458	CcSEcCtD
Gadoxetate—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	7.86e-05	0.000455	CcSEcCtD
Gadoxetate—Fatigue—Doxorubicin—urinary bladder cancer	7.85e-05	0.000454	CcSEcCtD
Gadoxetate—ABCC3—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	7.85e-05	0.00199	CbGpPWpGaD
Gadoxetate—Urticaria—Epirubicin—urinary bladder cancer	7.82e-05	0.000452	CcSEcCtD
Gadoxetate—Constipation—Doxorubicin—urinary bladder cancer	7.79e-05	0.000451	CcSEcCtD
Gadoxetate—Abdominal pain—Epirubicin—urinary bladder cancer	7.78e-05	0.00045	CcSEcCtD
Gadoxetate—Body temperature increased—Epirubicin—urinary bladder cancer	7.78e-05	0.00045	CcSEcCtD
Gadoxetate—SLCO1B3—Metabolism—PRSS3—urinary bladder cancer	7.75e-05	0.00196	CbGpPWpGaD
Gadoxetate—Hypersensitivity—Methotrexate—urinary bladder cancer	7.75e-05	0.000448	CcSEcCtD
Gadoxetate—ABCC4—Platelet activation, signaling and aggregation—IGF1—urinary bladder cancer	7.64e-05	0.00193	CbGpPWpGaD
Gadoxetate—ABCC3—Metabolism—CYP4B1—urinary bladder cancer	7.6e-05	0.00192	CbGpPWpGaD
Gadoxetate—Asthenia—Methotrexate—urinary bladder cancer	7.54e-05	0.000437	CcSEcCtD
Gadoxetate—Feeling abnormal—Doxorubicin—urinary bladder cancer	7.5e-05	0.000434	CcSEcCtD
Gadoxetate—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	7.44e-05	0.000431	CcSEcCtD
Gadoxetate—Pruritus—Methotrexate—urinary bladder cancer	7.44e-05	0.000431	CcSEcCtD
Gadoxetate—ABCC4—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	7.38e-05	0.00187	CbGpPWpGaD
Gadoxetate—SLCO1B1—Metabolism—GSTZ1—urinary bladder cancer	7.25e-05	0.00184	CbGpPWpGaD
Gadoxetate—Hypersensitivity—Epirubicin—urinary bladder cancer	7.25e-05	0.00042	CcSEcCtD
Gadoxetate—Urticaria—Doxorubicin—urinary bladder cancer	7.23e-05	0.000419	CcSEcCtD
Gadoxetate—Abdominal pain—Doxorubicin—urinary bladder cancer	7.2e-05	0.000417	CcSEcCtD
Gadoxetate—Body temperature increased—Doxorubicin—urinary bladder cancer	7.2e-05	0.000417	CcSEcCtD
Gadoxetate—Diarrhoea—Methotrexate—urinary bladder cancer	7.19e-05	0.000416	CcSEcCtD
Gadoxetate—ABCC3—Metabolism—SLC19A1—urinary bladder cancer	7.18e-05	0.00182	CbGpPWpGaD
Gadoxetate—Asthenia—Epirubicin—urinary bladder cancer	7.06e-05	0.000409	CcSEcCtD
Gadoxetate—ABCC4—Platelet activation, signaling and aggregation—RHOA—urinary bladder cancer	7e-05	0.00177	CbGpPWpGaD
Gadoxetate—ABCC3—Metabolism—PRSS3—urinary bladder cancer	6.99e-05	0.00177	CbGpPWpGaD
Gadoxetate—Pruritus—Epirubicin—urinary bladder cancer	6.96e-05	0.000403	CcSEcCtD
Gadoxetate—Dizziness—Methotrexate—urinary bladder cancer	6.95e-05	0.000402	CcSEcCtD
Gadoxetate—SLCO1B1—Metabolism—GSTO2—urinary bladder cancer	6.87e-05	0.00174	CbGpPWpGaD
Gadoxetate—SLCO1B1—Metabolism—NAT1—urinary bladder cancer	6.87e-05	0.00174	CbGpPWpGaD
Gadoxetate—ABCC4—Hemostasis—IFNA2—urinary bladder cancer	6.81e-05	0.00173	CbGpPWpGaD
Gadoxetate—SLCO1B1—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	6.76e-05	0.00171	CbGpPWpGaD
Gadoxetate—Diarrhoea—Epirubicin—urinary bladder cancer	6.73e-05	0.00039	CcSEcCtD
Gadoxetate—Hypersensitivity—Doxorubicin—urinary bladder cancer	6.71e-05	0.000388	CcSEcCtD
Gadoxetate—ABCC4—Ectoderm Differentiation—MYC—urinary bladder cancer	6.69e-05	0.00169	CbGpPWpGaD
Gadoxetate—Vomiting—Methotrexate—urinary bladder cancer	6.69e-05	0.000387	CcSEcCtD
Gadoxetate—Rash—Methotrexate—urinary bladder cancer	6.63e-05	0.000384	CcSEcCtD
Gadoxetate—Dermatitis—Methotrexate—urinary bladder cancer	6.62e-05	0.000383	CcSEcCtD
Gadoxetate—Headache—Methotrexate—urinary bladder cancer	6.59e-05	0.000381	CcSEcCtD
Gadoxetate—Asthenia—Doxorubicin—urinary bladder cancer	6.53e-05	0.000378	CcSEcCtD
Gadoxetate—Dizziness—Epirubicin—urinary bladder cancer	6.51e-05	0.000377	CcSEcCtD
Gadoxetate—Pruritus—Doxorubicin—urinary bladder cancer	6.44e-05	0.000373	CcSEcCtD
Gadoxetate—SLCO1B1—Metabolism—UGT2B7—urinary bladder cancer	6.29e-05	0.00159	CbGpPWpGaD
Gadoxetate—Vomiting—Epirubicin—urinary bladder cancer	6.26e-05	0.000362	CcSEcCtD
Gadoxetate—Nausea—Methotrexate—urinary bladder cancer	6.25e-05	0.000361	CcSEcCtD
Gadoxetate—Diarrhoea—Doxorubicin—urinary bladder cancer	6.23e-05	0.000361	CcSEcCtD
Gadoxetate—ABCC2—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	6.22e-05	0.00158	CbGpPWpGaD
Gadoxetate—SLCO1B3—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	6.22e-05	0.00157	CbGpPWpGaD
Gadoxetate—Rash—Epirubicin—urinary bladder cancer	6.2e-05	0.000359	CcSEcCtD
Gadoxetate—Dermatitis—Epirubicin—urinary bladder cancer	6.2e-05	0.000359	CcSEcCtD
Gadoxetate—SLCO1B3—Metabolism—TYMP—urinary bladder cancer	6.2e-05	0.00157	CbGpPWpGaD
Gadoxetate—Headache—Epirubicin—urinary bladder cancer	6.16e-05	0.000357	CcSEcCtD
Gadoxetate—Dizziness—Doxorubicin—urinary bladder cancer	6.02e-05	0.000348	CcSEcCtD
Gadoxetate—SLCO1B3—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	5.95e-05	0.00151	CbGpPWpGaD
Gadoxetate—ABCC4—Platelet activation, signaling and aggregation—IL2—urinary bladder cancer	5.87e-05	0.00149	CbGpPWpGaD
Gadoxetate—Nausea—Epirubicin—urinary bladder cancer	5.84e-05	0.000338	CcSEcCtD
Gadoxetate—SLCO1B1—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	5.84e-05	0.00148	CbGpPWpGaD
Gadoxetate—Vomiting—Doxorubicin—urinary bladder cancer	5.79e-05	0.000335	CcSEcCtD
Gadoxetate—Rash—Doxorubicin—urinary bladder cancer	5.74e-05	0.000332	CcSEcCtD
Gadoxetate—Dermatitis—Doxorubicin—urinary bladder cancer	5.74e-05	0.000332	CcSEcCtD
Gadoxetate—Headache—Doxorubicin—urinary bladder cancer	5.7e-05	0.00033	CcSEcCtD
Gadoxetate—SLCO1B1—Metabolism—CYP4B1—urinary bladder cancer	5.66e-05	0.00143	CbGpPWpGaD
Gadoxetate—ABCC3—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	5.61e-05	0.00142	CbGpPWpGaD
Gadoxetate—SLCO1B3—Metabolism—NAT2—urinary bladder cancer	5.6e-05	0.00142	CbGpPWpGaD
Gadoxetate—ABCC3—Metabolism—TYMP—urinary bladder cancer	5.59e-05	0.00142	CbGpPWpGaD
Gadoxetate—Nausea—Doxorubicin—urinary bladder cancer	5.41e-05	0.000313	CcSEcCtD
Gadoxetate—ABCC3—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	5.37e-05	0.00136	CbGpPWpGaD
Gadoxetate—SLCO1B1—Metabolism—SLC19A1—urinary bladder cancer	5.34e-05	0.00135	CbGpPWpGaD
Gadoxetate—SLCO1B1—Metabolism—PRSS3—urinary bladder cancer	5.21e-05	0.00132	CbGpPWpGaD
Gadoxetate—ABCC4—Platelet activation, signaling and aggregation—SRC—urinary bladder cancer	5.12e-05	0.0013	CbGpPWpGaD
Gadoxetate—ABCC3—Metabolism—NAT2—urinary bladder cancer	5.06e-05	0.00128	CbGpPWpGaD
Gadoxetate—SLCO1B3—Metabolism—RRM2—urinary bladder cancer	4.84e-05	0.00123	CbGpPWpGaD
Gadoxetate—ABCC4—Hemostasis—PLAU—urinary bladder cancer	4.83e-05	0.00122	CbGpPWpGaD
Gadoxetate—SLCO1B3—Metabolism—ENO2—urinary bladder cancer	4.48e-05	0.00113	CbGpPWpGaD
Gadoxetate—SLCO1B3—Metabolism—HPGDS—urinary bladder cancer	4.48e-05	0.00113	CbGpPWpGaD
Gadoxetate—SLCO1B3—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	4.45e-05	0.00113	CbGpPWpGaD
Gadoxetate—ABCC3—Metabolism—RRM2—urinary bladder cancer	4.37e-05	0.00111	CbGpPWpGaD
Gadoxetate—SLCO1B3—Metabolism—GSTT1—urinary bladder cancer	4.35e-05	0.0011	CbGpPWpGaD
Gadoxetate—SLCO1B3—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	4.28e-05	0.00108	CbGpPWpGaD
Gadoxetate—SLCO1B1—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	4.18e-05	0.00106	CbGpPWpGaD
Gadoxetate—SLCO1B1—Metabolism—TYMP—urinary bladder cancer	4.16e-05	0.00105	CbGpPWpGaD
Gadoxetate—SLCO1B3—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	4.07e-05	0.00103	CbGpPWpGaD
Gadoxetate—ABCC3—Metabolism—ENO2—urinary bladder cancer	4.04e-05	0.00102	CbGpPWpGaD
Gadoxetate—ABCC3—Metabolism—HPGDS—urinary bladder cancer	4.04e-05	0.00102	CbGpPWpGaD
Gadoxetate—ABCC3—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	4.02e-05	0.00102	CbGpPWpGaD
Gadoxetate—SLCO1B1—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	4e-05	0.00101	CbGpPWpGaD
Gadoxetate—ABCC4—Hemostasis—CREBBP—urinary bladder cancer	3.99e-05	0.00101	CbGpPWpGaD
Gadoxetate—ABCC4—Hemostasis—IGF1—urinary bladder cancer	3.94e-05	0.000997	CbGpPWpGaD
Gadoxetate—ABCC3—Metabolism—GSTT1—urinary bladder cancer	3.92e-05	0.000993	CbGpPWpGaD
Gadoxetate—ABCC3—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	3.86e-05	0.000978	CbGpPWpGaD
Gadoxetate—SLCO1B1—Metabolism—NAT2—urinary bladder cancer	3.77e-05	0.000954	CbGpPWpGaD
Gadoxetate—ABCC3—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	3.67e-05	0.00093	CbGpPWpGaD
Gadoxetate—SLCO1B3—Metabolism—NQO1—urinary bladder cancer	3.61e-05	0.000915	CbGpPWpGaD
Gadoxetate—ABCC4—Hemostasis—RHOA—urinary bladder cancer	3.61e-05	0.000914	CbGpPWpGaD
Gadoxetate—SLCO1B3—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	3.5e-05	0.000887	CbGpPWpGaD
Gadoxetate—ABCC4—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	3.45e-05	0.000874	CbGpPWpGaD
Gadoxetate—ABCC3—Metabolism—NQO1—urinary bladder cancer	3.26e-05	0.000825	CbGpPWpGaD
Gadoxetate—SLCO1B1—Metabolism—RRM2—urinary bladder cancer	3.25e-05	0.000823	CbGpPWpGaD
Gadoxetate—ABCC3—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	3.16e-05	0.000801	CbGpPWpGaD
Gadoxetate—SLCO1B3—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	3.06e-05	0.000774	CbGpPWpGaD
Gadoxetate—ABCC4—Hemostasis—IL2—urinary bladder cancer	3.03e-05	0.000766	CbGpPWpGaD
Gadoxetate—SLCO1B3—Metabolism—GSTP1—urinary bladder cancer	3.01e-05	0.000763	CbGpPWpGaD
Gadoxetate—SLCO1B1—Metabolism—ENO2—urinary bladder cancer	3.01e-05	0.000762	CbGpPWpGaD
Gadoxetate—SLCO1B1—Metabolism—HPGDS—urinary bladder cancer	3.01e-05	0.000762	CbGpPWpGaD
Gadoxetate—SLCO1B1—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	2.99e-05	0.000758	CbGpPWpGaD
Gadoxetate—SLCO1B1—Metabolism—GSTT1—urinary bladder cancer	2.92e-05	0.000739	CbGpPWpGaD
Gadoxetate—SLCO1B3—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	2.91e-05	0.000738	CbGpPWpGaD
Gadoxetate—ABCC2—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	2.91e-05	0.000737	CbGpPWpGaD
Gadoxetate—SLCO1B1—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	2.88e-05	0.000728	CbGpPWpGaD
Gadoxetate—SLCO1B3—Metabolism—TYMS—urinary bladder cancer	2.8e-05	0.000709	CbGpPWpGaD
Gadoxetate—SLCO1B3—Metabolism—NCOR1—urinary bladder cancer	2.77e-05	0.000701	CbGpPWpGaD
Gadoxetate—SLCO1B3—Metabolism—GSTM1—urinary bladder cancer	2.77e-05	0.000701	CbGpPWpGaD
Gadoxetate—ABCC3—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	2.76e-05	0.000698	CbGpPWpGaD
Gadoxetate—SLCO1B1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	2.73e-05	0.000692	CbGpPWpGaD
Gadoxetate—ABCC3—Metabolism—GSTP1—urinary bladder cancer	2.72e-05	0.000688	CbGpPWpGaD
Gadoxetate—ABCC4—Hemostasis—EP300—urinary bladder cancer	2.72e-05	0.000688	CbGpPWpGaD
Gadoxetate—SLCO1B3—Metabolism—GPX1—urinary bladder cancer	2.65e-05	0.000671	CbGpPWpGaD
Gadoxetate—ABCC4—Hemostasis—SRC—urinary bladder cancer	2.64e-05	0.000669	CbGpPWpGaD
Gadoxetate—ABCC3—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	2.63e-05	0.000666	CbGpPWpGaD
Gadoxetate—SLCO1B3—Metabolism—ERCC2—urinary bladder cancer	2.6e-05	0.000659	CbGpPWpGaD
Gadoxetate—ABCC3—Metabolism—TYMS—urinary bladder cancer	2.53e-05	0.00064	CbGpPWpGaD
Gadoxetate—ABCC3—Metabolism—NCOR1—urinary bladder cancer	2.5e-05	0.000633	CbGpPWpGaD
Gadoxetate—ABCC3—Metabolism—GSTM1—urinary bladder cancer	2.5e-05	0.000633	CbGpPWpGaD
Gadoxetate—SLCO1B3—Metabolism—MTHFR—urinary bladder cancer	2.45e-05	0.00062	CbGpPWpGaD
Gadoxetate—SLCO1B1—Metabolism—NQO1—urinary bladder cancer	2.43e-05	0.000615	CbGpPWpGaD
Gadoxetate—ABCC3—Metabolism—GPX1—urinary bladder cancer	2.39e-05	0.000606	CbGpPWpGaD
Gadoxetate—SLCO1B1—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	2.35e-05	0.000596	CbGpPWpGaD
Gadoxetate—ABCC3—Metabolism—ERCC2—urinary bladder cancer	2.35e-05	0.000595	CbGpPWpGaD
Gadoxetate—ABCC3—Metabolism—MTHFR—urinary bladder cancer	2.21e-05	0.000559	CbGpPWpGaD
Gadoxetate—ABCC4—Hemostasis—KRAS—urinary bladder cancer	2.19e-05	0.000554	CbGpPWpGaD
Gadoxetate—SLCO1B1—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	2.05e-05	0.00052	CbGpPWpGaD
Gadoxetate—SLCO1B1—Metabolism—GSTP1—urinary bladder cancer	2.02e-05	0.000513	CbGpPWpGaD
Gadoxetate—SLCO1B3—Metabolism—PPARG—urinary bladder cancer	1.98e-05	0.000502	CbGpPWpGaD
Gadoxetate—SLCO1B1—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.96e-05	0.000496	CbGpPWpGaD
Gadoxetate—ABCC4—Hemostasis—TP53—urinary bladder cancer	1.94e-05	0.000492	CbGpPWpGaD
Gadoxetate—SLCO1B3—Metabolism—CREBBP—urinary bladder cancer	1.91e-05	0.000483	CbGpPWpGaD
Gadoxetate—SLCO1B1—Metabolism—TYMS—urinary bladder cancer	1.88e-05	0.000477	CbGpPWpGaD
Gadoxetate—SLCO1B1—Metabolism—NCOR1—urinary bladder cancer	1.86e-05	0.000471	CbGpPWpGaD
Gadoxetate—SLCO1B1—Metabolism—GSTM1—urinary bladder cancer	1.86e-05	0.000471	CbGpPWpGaD
Gadoxetate—ABCC4—Hemostasis—HRAS—urinary bladder cancer	1.86e-05	0.000471	CbGpPWpGaD
Gadoxetate—ABCC3—Metabolism—PPARG—urinary bladder cancer	1.79e-05	0.000453	CbGpPWpGaD
Gadoxetate—SLCO1B1—Metabolism—GPX1—urinary bladder cancer	1.78e-05	0.000451	CbGpPWpGaD
Gadoxetate—SLCO1B1—Metabolism—ERCC2—urinary bladder cancer	1.75e-05	0.000443	CbGpPWpGaD
Gadoxetate—ABCC3—Metabolism—CREBBP—urinary bladder cancer	1.72e-05	0.000435	CbGpPWpGaD
Gadoxetate—SLCO1B1—Metabolism—MTHFR—urinary bladder cancer	1.64e-05	0.000416	CbGpPWpGaD
Gadoxetate—SLCO1B3—Metabolism—PTGS2—urinary bladder cancer	1.56e-05	0.000395	CbGpPWpGaD
Gadoxetate—ABCC3—Metabolism—PTGS2—urinary bladder cancer	1.41e-05	0.000357	CbGpPWpGaD
Gadoxetate—SLCO1B3—Metabolism—PTEN—urinary bladder cancer	1.36e-05	0.000345	CbGpPWpGaD
Gadoxetate—SLCO1B1—Metabolism—PPARG—urinary bladder cancer	1.33e-05	0.000338	CbGpPWpGaD
Gadoxetate—SLCO1B3—Metabolism—EP300—urinary bladder cancer	1.3e-05	0.000329	CbGpPWpGaD
Gadoxetate—SLCO1B1—Metabolism—CREBBP—urinary bladder cancer	1.28e-05	0.000324	CbGpPWpGaD
Gadoxetate—ABCC3—Metabolism—PTEN—urinary bladder cancer	1.23e-05	0.000311	CbGpPWpGaD
Gadoxetate—ABCC3—Metabolism—EP300—urinary bladder cancer	1.17e-05	0.000297	CbGpPWpGaD
Gadoxetate—SLCO1B1—Metabolism—PTGS2—urinary bladder cancer	1.05e-05	0.000266	CbGpPWpGaD
Gadoxetate—SLCO1B1—Metabolism—PTEN—urinary bladder cancer	9.14e-06	0.000232	CbGpPWpGaD
Gadoxetate—SLCO1B1—Metabolism—EP300—urinary bladder cancer	8.72e-06	0.000221	CbGpPWpGaD
